NSE: SAILIFE · 6 November 2026
- Sai Life Sciences has risen 15.46% over 2 trading sessions; today's move is +11.95%.
- Sai Life Sciences submitted its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company reported a 23% year-on-year rise in quarterly revenue to ₹659 crore, while half-yearly revenue reached ₹1,213 crore with an EBITDA of ₹335 crore. Management highlighted robust operating performance across both CRO and CDMO segments along with ongoing capacity expansion investments.
- Trading volume was 27.49 times the 20-day average daily volume.
Sai Life Sciences share price: 15.46% rise over 2 trading sessions
Sai Life Sciences Ltd. (SAILIFE) shares surged by 11.95% today, closing at ₹1,785.10 after touching an intraday high of ₹1,814.90 and a low of ₹1,614.90.
The broader market demonstrated positive momentum, with the benchmark Nifty advancing 2.01% and the Nifty Pharma sector gaining 1.21%. Sai Life Sciences outperformed both the wider market and its sector peer group, building on strong recent momentum that includes a 5-day return of 14.61% and a 20-day return of 18.56%.
Today's strong price action coincides with the release of the company's financial and operational updates for the quarter ended September 30, 2026.
1.32 crore shares traded by 6 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 4.81 lakh shares (27.49 times). The five-day average daily volume was 6.33 lakh shares. Separately, the NSE report for 6 November 2026 showed 17.61 lakh shares delivered, representing 13.31% of that day’s traded volume. The same report recorded 451,686 trades.
The stock's 11.95% surge with significant volume expansion aligns closely with the release of quarterly financial results showing solid revenue and EBITDA growth, supported by positive broader healthcare sector sentiment.
Latest Company Developments
Sai Life Sciences submitted its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company reported a 23% year-on-year rise in quarterly revenue to ₹659 crore, while half-yearly revenue reached ₹1,213 crore with an EBITDA of ₹335 crore. Management highlighted robust operating performance across both CRO and CDMO segments along with ongoing capacity expansion investments.
Provides official financial metrics and growth figures reflecting business momentum across the company's core operating segments.
The Board of Directors approved the appointment of new senior management personnel effective November 5, 2026. These appointments include Mr. Sidhartha Das as Senior Vice President & Head of Human Resources, Mr. Vijay Kumar Suthari as Vice President & Head of Quality & Regulatory Affairs, and Mr. Sriram Gopalakrishnan as Senior Vice President of Corporate Communications.
Strengthens key leadership functions across human resources, regulatory compliance, and corporate communications during a growth phase.
a press release dated November 05, 2026, titled "Press Release on Financial Results ".
Sai Life Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Sai Life soars 10%, hits record high on strong Q2 earnings Business Standard
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 29.56% on 30 September 2026. This compares with 29.47% on 30 June 2026, a change of +0.09 percentage points.
The filing reported 31 MF/UTI holders.
Research & Brokerage Views
What to Watch Next
- Execution and ramp-up of new capacity following ₹621 crore invested in capital expenditure during H1 FY27
- Performance of CRO and CDMO revenue segments in subsequent quarters
- Client engagement developments and scaling of integrated outsourcing partnerships
- Delivery volume trends and institutional participation levels relative to the 20-day average
Other Dated Coverage
- Sai Life Sciences Share Price Today: Why SAILIFE Is Rising 1.03% | 3 November 2026 — 3 November 2026
- Sai Life Sciences Share Price Today: Why SAILIFE Is Falling 0.98% | 2 November 2026 — 2 November 2026
More Sai Life Sciences news and dated analysis →
Frequently Asked Questions
What is the latest Sai Life Sciences company news?
Sai Life Sciences submitted its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company reported a 23% year-on-year rise in quarterly revenue to ₹659 crore, while half-yearly revenue reached ₹1,213 crore with an EBITDA of ₹335 crore. Management highlighted robust operating performance across both CRO and CDMO segments along with ongoing capacity expansion investments.
How strong was Sai Life Sciences’s trading volume?
1.32 crore shares traded, 27.49 times the 20-day average daily volume. The price and volume data are dated 6 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.